Chemopreventive effect of Betulinic acid via mTOR -Caspases/Bcl2/Bax apoptotic signaling in pancreatic cancer

doi:10.1186/s12906-020-02976-7

科研成果详情

题名	Chemopreventive effect of Betulinic acid via mTOR -Caspases/Bcl2/Bax apoptotic signaling in pancreatic cancer
作者	Guo, Yangyang; Zhu, Hengyue; Weng, Min; Wang, Cheng; Sun, Linxiao
发表日期	2020-06-08
发表期刊	BMC COMPLEMENTARY MEDICINE AND THERAPIES 影响因子和分区
语种	英语
原始文献类型	Article
关键词	Betulinic acid mTOR signaling Apoptosis Pancreatic cancer
其他关键词	IN-VITRO ; CELL ; PROLIFERATION ; DERIVATIVES ; INHIBITOR ; PROGRESS ; PATHWAY ; VIVO
摘要	Background: Pancreatic cancer is aggressive with no symptoms until the advanced stage reached. The increased resistance of pancreatic cancer to chemotherapy demonstrates a dilemma in the clinical field. Hence, it is a matter of great urgency to develop an effective drug to treat patients with pancreatic cancer. Betulinic acid is a major triterpene isolated from spina date seed. Several studies have suggested its low toxicity and side effects to patients with malaria and inflammation. However, relevant studies on betulinic acid in inhibiting cancer were insufficient and the molecular mechanism was unclear. This study aimed to systematically explore the potential anti-cancer functions of betulinic acid in pancreatic cancer, and investigate its underlying molecular mechanism. Methods: The Counting Kit-8 assay, colony formation, transwell invasion assay, wound healing assay, flow cytometry and xenograft nude mice model were used to evaluate the effect of betulinic acid on the proliferation, invasion and migration ability of pancreatic cancer cells. Results: Our results showed that betulinic acid obviously suppressed pancreatic cancer both in vitro and in vivo in a dose-dependent manner. We also determined that betulinic acid inhibited pancreatic cancer by specifically targeting mTOR signaling rather than Nrf2 or JAK2. Conclusions: These findings clarify that betulinic acid is a potential and valuable anticancer agent for pancreatic cancer, and indicate the specific molecular target of betulinic acid.
资助项目	Natural Science Foundation of Zhejiang ProvinceNatural Science Foundation of Zhejiang Province [Q20H030022]
出版者	BMC
出版地	LONDON
ISSN	2662-7671
EISSN	2662-7671
卷号	20 期号:1 页码:178
DOI	10.1186/s12906-020-02976-7
页数	11
WOS类目	Integrative & Complementary Medicine
WOS研究方向	Integrative & Complementary Medicine
WOS记录号	WOS:000550369900002
收录类别	SCIE ; PUBMED ; SCOPUS
URL	查看原文
PubMed ID	32513155
PMC记录号	PMC7282238
SCOPUSEID	2-s2.0-85096058782
通讯作者地址	[Wang, Cheng]Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of Zhejiang Province,Zhejiang Provincial Top Key Discipline in Surgery,Wenzhou Medical University First Affiliated Hospital,Wenzhou,China ; [Sun, Linxiao]Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of Zhejiang Province,Zhejiang Provincial Top Key Discipline in Surgery,Wenzhou Medical University First Affiliated Hospital,Wenzhou,China
Scopus学科分类	Complementary and Alternative Medicine
引用统计	被引频次：17[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/19446
专题	附属第一医院
通讯作者	Wang, Cheng; Sun, Linxiao
作者单位	Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of Zhejiang Province,Zhejiang Provincial Top Key Discipline in Surgery,Wenzhou Medical University First Affiliated Hospital,Wenzhou,China
第一作者单位	附属第一医院
通讯作者单位	附属第一医院
第一作者的第一单位	附属第一医院
推荐引用方式 GB/T 7714	Guo, Yangyang,Zhu, Hengyue,Weng, Min,et al. Chemopreventive effect of Betulinic acid via mTOR -Caspases/Bcl2/Bax apoptotic signaling in pancreatic cancer[J]. BMC COMPLEMENTARY MEDICINE AND THERAPIES,2020,20(1):178.
APA	Guo, Yangyang, Zhu, Hengyue, Weng, Min, Wang, Cheng, & Sun, Linxiao. (2020). Chemopreventive effect of Betulinic acid via mTOR -Caspases/Bcl2/Bax apoptotic signaling in pancreatic cancer. BMC COMPLEMENTARY MEDICINE AND THERAPIES, 20(1), 178.
MLA	Guo, Yangyang,et al."Chemopreventive effect of Betulinic acid via mTOR -Caspases/Bcl2/Bax apoptotic signaling in pancreatic cancer".BMC COMPLEMENTARY MEDICINE AND THERAPIES 20.1(2020):178.